Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session and Request for Comments

Riepilogo

The United States Patent and Trademark Office (USPTO), Department of Commerce, in collaboration with the United States Food and Drug Administration (FDA), Department of Health and Human Services, is extending the written comment period for the notice titled "Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session and Request for Comments" that was published in the Federal Register on November 7, 2022, until March 10, 2023.